- New data evaluating investigational compound
REOLYSIN® in combination with paclitaxel in metastatic
Breast Cancer
- Growing understanding of the potential role of
REOLYSIN® in treating a broad range of
cancers
CALGARY, March 2, 2017 /PRNewswire/ - Oncolytics
Biotech® Inc. (Oncolytics or the Company) (TSX:ONC)
(OTCQX:ONCYF) today announced that the Canadian Cancer Trials
Group (CCTG, formerly known as the National Cancer Institute of
Canada) will present clinical
trial data evaluating the Company's investigational immuno-oncology
viral-agent, REOLYSIN®, during the American
Academy of Cancer Research (AACR) Annual Meeting, April 1-5, in Washington, DC.
"We're very pleased that CCTG has this opportunity to present
final data from the metastatic breast cancer study to the
international scientific community," said Dr. Matt Coffey, President & CEO of
Oncolytics.
The abstract, authored by Bernstein et al, "A randomized
(RCT) phase II study of oncolytic reovirus (pelareorep) plus
standard weekly paclitaxel (P) as therapy for metastatic breast
cancer (mBC)" will be available on the AACR website on March 31, 2017. Submitted by the CCTG, the
abstract covers final results from IND 213, an open-label,
randomized, non-blinded Phase 2 study to assess the therapeutic
combination of intravenously-administered
REOLYSIN given in combination with paclitaxel
versus paclitaxel alone in patients with advanced or metastatic
breast cancer.
Oncolytics would like to thank the patients that participated in
this study, the CCTG and all the physicians and nurses
involved.
About Breast Cancer
The American Cancer Society
estimates there will be 255,180 new cases of breast cancer
diagnosed in the United States and
41,070 deaths from the disease in 2017.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an immuno-oncology
viral-agent, as a potential treatment for a variety of tumor types.
The compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
potentially treat a variety of cancers. Oncolytics' clinical
development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis; immuno-therapy
combinations to produce adaptive immune responses; and immune
modulator (IMiD) combinations to facilitate innate immune
responses. For further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's expectations related to the Phase 2 clinical trial in
breast cancer, future trials in this indication, and the Company's
belief as to the potential of REOLYSIN as a cancer therapeutic,
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of
REOLYSIN as a cancer treatment, the tolerability of REOLYSIN
outside a controlled test, the success and timely completion of
clinical studies and trials, the Company's ability to successfully
commercialize REOLYSIN, uncertainties related to the research,
development and manufacturing of pharmaceuticals, changes in
technology, general changes to the economic environment and
uncertainties related to the regulatory process. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors should consider statements that include the
words "believes", "expects", "anticipates", "intends", "estimates",
"plans", "projects", "should", or other expressions that are
predictions of or indicate future events or trends, to be uncertain
and forward-looking. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.
SOURCE Oncolytics Biotech Inc.